Neurociencia del consumo y dependencia de sustancias psicoactivas
Neurociencia del consumo y dependencia de sustancias psicoactivas Neurociencia del consumo y dependencia de sustancias psicoactivas
6. TRASTORNOS CONCURRENTESCarol G y colab. (2001) A preliminary investigation of cocaine craving amongpersons with and without schizophrenia. Psychiatry Services, 52:1029–1031.Cesarec Z, Nyman AK (1985) Differential response to amphetamine in schizophrenia.Acta Psychiatrica Scandinavica, 71:523–538.Chabrol H, Armitage J (2002) Substance use and the development of antisocialpersonality in depressed adolescents. Archives of General Psychiatry, 59:665.Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substanceabuse comorbidity in schizophrenia. Biological Psychiatry, 50:71–83.Chaput Y, de Montigny C, Blier P (1991) Presynaptic and postsynaptic modificationsof the serotonin system by long-term administration of antidepressanttreatments: an in vivo electrophysiologic study in the rat.Neuropsychopharmacology, 5:219–229.Claghorn J y colab. (1987) The risks and benefits of clozapine versus chloropromazine.Journal of Clinical Psychopharmacology, 7:377–384.Clarke PB y colab. (1985) Nicotine binding in rat brain: autoradiographic comparisonof [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin.Journal of Neuroscience, 5:1307–1315.Compton III WM y colab. (2000) Psychiatric disorders among drug dependentsubjects: are they primary or secondary? American Journal on Addictions,9:126–134.Compton III WM y colab. (2000) Substance dependence and other psychiatricdisorders among drug dependent subjects: race and gender correlates. AmericanJournal on Addictions, 9:113-125.Coppen A (1967) The biochemistry of affective disorders. British Journal ofPsychiatry, 113:1237–1264.Cornelius JR (1995) Preliminary report: double-blind, placebo-controlled studyof fluoxetine in depressed alcoholics. Psychopharmacology Bulletin,31:297–303.Cuesta MJ, Peralta V, Zarzuela A (2001) Effects of olanzapine and other antipsychoticson cognitive function in chronic schizophrenia: a longitudinal study.Schizophrenia Research, 48:17–28.Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia andtheir correlates. Journal of Nervous and Mental Disorders, 180:589–592.Dalack GW, Healy DJ, Meador-Woodruff JH (1998) Nicotine dependence inschizophrenia: clinical phenomena and laboratory findings. American Journal ofPsychiatry, 155:1490–1501.Dalack GW y colab. (1995) Mood, major depression, and fluoxentine responsein cigarette smokers. American Journal of Psychiatry, 152:398–403.Dani JA, Heinemann S (1996) Molecular and cellular aspects of nicotine abuse.Neuron, 16:905–908.Decina P y colab. (1990) Cigarette smoking and neuroleptic-induced parkinsonism.Biological Psychiatry, 28:502–508.de Leon J y colab. (1995) Schizophrenia and smoking: an epidemiological surveyin a state hospital. American Journal of Psychiatry, 152:453–455.193
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASDelgado PL y colab. (1990) Serotonin function and the mechanism of antidepressantaction: reversal of antidepressant-induced remission by rapid depletionof plasma tryptophan. Archives of General Psychiatry, 47:411–418.Delgado PL y colab. (1991) Rapid serotonin depletion as a provocative challengetest for patients with major depression: relevance to antidepressant action andthe neurobiology of depression. Psychopharmacology Bulletin, 27:321–330.Delgado PL y colab. (1993) Monoamines and the mechanism of antidepressantaction: effects of catecholamine depletion on mood of patients treated with antidepressants.Psychopharmacology Bulletin, 29:389–396.Delgado PL y colab. (1994) Serotonin and the neurobiology of depression:effects of tryptophan depletion in drug-free depressed patients. Archives ofGeneral Psychiatry, 51:865–874.de Montigny C, Aghajanian GK (1978) Tricyclic antidepressants: long-termtreatment increases responsivity of rat forebrain neurons to serotonin. Science,202:1303–1306.Desai NG y colab. (1984) Treatment of negative schizophrenia with d-amphetamine.American Journal of Psychiatry, 141:723–724.Di Chiara G y colab. (1999) Drug addiction as a disorder of associative learning:role of nucleus accumbens shell/extended amygdala dopamine. Annals of theNew York Acadamy of Sciences, 877:461–485.Diwan A y colab. (1998) Differential prevalence of cigarette smoking in patientswith schizophrenic vs mood disorders. Schizophrenia Research, 33:113–118.Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalenceand impact outcomes. Schizophrenia Research, 35 Suppl: S93–S100.Dixon L y colab. (1990) Acute effects of drug abuse in schizophrenic patients:clinical observations and patients’ self-reports. Schizophrenia Bulletin, 16:69–79.Dixon L y colab. (1991) Drug abuse in schizophrenic patients: clinical correlatesand reasons for use. American Journal of Psychiatry, 148:224–230.Duncan GE, Sheitman BB, Lieberman JA (1999) An integrated view of pathophysiologicalmodels of schizophrenia. Brain Research Reviews, 29:250–264.Edwards G (1990) Withdrawal symptoms and alcohol dependence: fruitful mysteries.British Journal of Addiction, 85:447–461.Ellenbogen MA y colab. (1996) Mood response to acute tryptophan depletionin healthy volunteers: sex differences and temporal stability.Neuropsychopharmacology, 15:465–474.Ellenbroek BA, Cools AR (2000) Animal models for the negative symptoms ofschizophrenia. Behavioural Pharmacology, 11:223–233.Escamilla MA y colab. (2002) Comorbidity of bipolar disorder and substanceabuse in Costa Rica: pedigree- and population-based studies. Journal of AffectiveDisorders, 71:71-83.Fatemi SH, Earle JA, McMenomy T (2000) Reduction in Reelin immunoreactivityin hippocampus of subjects with schizophrenia, bipolar disorder and majordepression. Molecular Psychiatry, 5:654–663.Feighner JP y colab. (1984) A double-blind study of bupropion and placebo in194
- Page 164 and 165: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 166 and 167: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 168 and 169: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 170 and 171: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 172 and 173: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 174 and 175: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 176 and 177: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 178 and 179: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 180 and 181: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 182 and 183: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 184 and 185: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 186 and 187: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 188 and 189: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 190 and 191: Capítulo 6Trastornos ConcurrentesI
- Page 192 and 193: 6. TRASTORNOS CONCURRENTES3. El uso
- Page 194 and 195: 6. TRASTORNOS CONCURRENTESy Meador-
- Page 196 and 197: 6. TRASTORNOS CONCURRENTESprobablem
- Page 198 and 199: 6. TRASTORNOS CONCURRENTESde drogas
- Page 200 and 201: 6. TRASTORNOS CONCURRENTESy Turski,
- Page 202 and 203: 6. TRASTORNOS CONCURRENTESEl víncu
- Page 204 and 205: 6. TRASTORNOS CONCURRENTESAlcohol y
- Page 206 and 207: 6. TRASTORNOS CONCURRENTESSerotonin
- Page 208 and 209: 6. TRASTORNOS CONCURRENTESFunción
- Page 210 and 211: 6. TRASTORNOS CONCURRENTESRECUADRO
- Page 212 and 213: 6. TRASTORNOS CONCURRENTEStos psiqu
- Page 216 and 217: 6. TRASTORNOS CONCURRENTESdepressio
- Page 218 and 219: 6. TRASTORNOS CONCURRENTESHall RG y
- Page 220 and 221: 6. TRASTORNOS CONCURRENTESKapur S,
- Page 222 and 223: 6. TRASTORNOS CONCURRENTESMansvelde
- Page 224 and 225: 6. TRASTORNOS CONCURRENTESPetty F (
- Page 226 and 227: 6. TRASTORNOS CONCURRENTESSevy S y
- Page 228: 6. TRASTORNOS CONCURRENTESlesions o
- Page 231 and 232: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 233 and 234: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 235 and 236: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 237 and 238: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 239 and 240: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 241 and 242: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 243 and 244: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 245 and 246: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 247 and 248: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 249 and 250: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 251 and 252: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 253 and 254: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 255 and 256: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 257 and 258: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 259 and 260: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 261 and 262: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 263 and 264: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASDelgado PL y colab. (1990) Serotonin function and the mechanism of anti<strong>de</strong>pressantaction: reversal of anti<strong>de</strong>pressant-induced remission by rapid <strong>de</strong>pletionof plasma tryptophan. Archives of General Psychiatry, 47:411–418.Delgado PL y colab. (1991) Rapid serotonin <strong>de</strong>pletion as a provocative challengetest for patients with major <strong>de</strong>pression: relevance to anti<strong>de</strong>pressant action andthe neurobiology of <strong>de</strong>pression. Psychopharmacology Bulletin, 27:321–330.Delgado PL y colab. (1993) Monoamines and the mechanism of anti<strong>de</strong>pressantaction: effects of catecholamine <strong>de</strong>pletion on mood of patients treated with anti<strong>de</strong>pressants.Psychopharmacology Bulletin, 29:389–396.Delgado PL y colab. (1994) Serotonin and the neurobiology of <strong>de</strong>pression:effects of tryptophan <strong>de</strong>pletion in drug-free <strong>de</strong>pressed patients. Archives ofGeneral Psychiatry, 51:865–874.<strong>de</strong> Montigny C, Aghajanian GK (1978) Tricyclic anti<strong>de</strong>pressants: long-termtreatment increases responsivity of rat forebrain neurons to serotonin. Science,202:1303–1306.Desai NG y colab. (1984) Treatment of negative schizophrenia with d-amphetamine.American Journal of Psychiatry, 141:723–724.Di Chiara G y colab. (1999) Drug addiction as a disor<strong>de</strong>r of associative learning:role of nucleus accumbens shell/exten<strong>de</strong>d amygdala dopamine. Annals of theNew York Acadamy of Sciences, 877:461–485.Diwan A y colab. (1998) Differential prevalence of cigarette smoking in patientswith schizophrenic vs mood disor<strong>de</strong>rs. Schizophrenia Research, 33:113–118.Dixon L (1999) Dual diagnosis of substance abuse in schizophrenia: prevalenceand impact outcomes. Schizophrenia Research, 35 Suppl: S93–S100.Dixon L y colab. (1990) Acute effects of drug abuse in schizophrenic patients:clinical observations and patients’ self-reports. Schizophrenia Bulletin, 16:69–79.Dixon L y colab. (1991) Drug abuse in schizophrenic patients: clinical correlatesand reasons for use. American Journal of Psychiatry, 148:224–230.Duncan GE, Sheitman BB, Lieberman JA (1999) An integrated view of pathophysiologicalmo<strong><strong>de</strong>l</strong>s of schizophrenia. Brain Research Reviews, 29:250–264.Edwards G (1990) Withdrawal symptoms and alcohol <strong>de</strong>pen<strong>de</strong>nce: fruitful mysteries.British Journal of Addiction, 85:447–461.Ellenbogen MA y colab. (1996) Mood response to acute tryptophan <strong>de</strong>pletionin healthy volunteers: sex differences and temporal stability.Neuropsychopharmacology, 15:465–474.Ellenbroek BA, Cools AR (2000) Animal mo<strong><strong>de</strong>l</strong>s for the negative symptoms ofschizophrenia. Behavioural Pharmacology, 11:223–233.Escamilla MA y colab. (2002) Comorbidity of bipolar disor<strong>de</strong>r and substanceabuse in Costa Rica: pedigree- and population-based studies. Journal of AffectiveDisor<strong>de</strong>rs, 71:71-83.Fatemi SH, Earle JA, McMenomy T (2000) Reduction in Reelin immunoreactivityin hippocampus of subjects with schizophrenia, bipolar disor<strong>de</strong>r and major<strong>de</strong>pression. Molecular Psychiatry, 5:654–663.Feighner JP y colab. (1984) A double-blind study of bupropion and placebo in194
Change language